Acute chest pain (ACP) is a common presenting symptom in clinical practice, often posing a diagnostic challenge for clinicians. It is crucial to promptly identify its cause, as it may be a manifestation of life-threatening conditions such as acute coronary syndrome (ACS).
Initial evaluation should include a thorough history and physical examination. The clinician should assess the patient's risk factors for coronary artery disease (CAD), the characteristics of the pain, and accompanying symptoms. Electrocardiogram (ECG) and cardiac biomarkers are essential in the early detection of myocardial ischemia.
When initial investigations are inconclusive, diagnostic imaging can provide further insights. Coronary computed tomography angiography (CCTA) is increasingly used in the evaluation of ACP due to its high negative predictive value. However, it should be used judiciously considering its associated radiation exposure.
Clinical decision rules such as the HEART score can guide clinicians in risk stratification and decision-making. These tools incorporate elements of history, ECG findings, age, risk factors, and troponin levels to predict the likelihood of major adverse cardiac events.
The management of ACP is guided by its underlying cause. In cases of suspected ACS, immediate reperfusion therapy is indicated. For non-cardiac chest pain, appropriate management includes symptom control and addressing the underlying cause.
In conclusion, the evaluation of ACP requires a systematic approach, incorporating clinical history, physical examination, diagnostic investigations, and risk stratification tools. Prompt identification and management of the underlying cause are essential to improve patient outcomes. As clinicians, maintaining a high index of suspicion and utilizing available diagnostic tools judiciously can aid in deciphering the enigma of acute chest pain.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation